The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2008NR2B as a Therapeutic Target in Parkinson's Disease
Objective/Rationale:
The loss of striatal dopamine that accompanies Parkinson’s disease disrupts the function of the neurotransmitter glutamate within this same region. Glutamate transmission involves...
-
Target Validation, 2008SIRT1 Activators as Therapy for Parkinson's Disease
Objective/Rationale:
Resveratrol is a compound that activates a protetin, SIRT1, which is known to protect against stresses associated with neurodegeneration, including oxidative damage and protein... -
Therapeutics Development Initiative, 2008Novel Gastric Retentive Controlled-release Dosage Forms of Levodopa/Carbidopa: in vivo Assessment in Pre-Clinical Models
Objective/Rationale:
The objective of this project is to develop gastric retentive controlled-release tablets of levodopa/carbidopa that will result in more constant blood levels of levodopa compared... -
Therapeutics Development Initiative, 2008Passive Immunotherapy for Parkinson's Disease based on Naturally Occurring Autoantibodies against alpha-Synuclein
Objective/Rationale:
We suggest a novel approach for the treatment of Parkinson's disease based on anti-alpha-synuclein monoclonal antibodies. This treatment concept offers a preventive approach in... -
Therapeutics Development Initiative, 2008Discovery of Novel Inhibitors of LRRK2 for the Treatment of Parkinson's Disease
Objective/Rationale:
A recent breakthrough in Parkinson’s disease research is the discovery that mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are associated with both the hereditary... -
Therapeutics Development Initiative, 2008GPR88, a new PD target involved in the modulation of basal ganglia circuitry
The receptor GPR88 is highly expressed in brain areas relevant for Parkinson's disease. GPR88 is an orphan receptor, i.e., a receptor with no known ligands. The neurobiological role and signalling...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.